GO:0016857 racemase and epimerase activity, acting on carbohydrates and derivatives: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016857 defines racemase and epimerase activity that alters the configuration of one or more chiral centers in carbohydrate molecules.
• These enzymes are essential for cell wall biosynthesis, nucleotide sugar interconversion, and glycan remodeling.
• Representative enzymes include UDP-N-acetylglucosamine 2-epimerase, UDP-galactose 4-epimerase, and mannuronate C-5 epimerase.
• Mechanistic studies reveal domain movements and active-site residues critical for catalysis.
• Dysregulation of these enzymes is linked to bacterial virulence, metabolic disorders, and cancer.
• CRISPR-based knockout, point mutation, and knock-in models enable precise functional dissection of these enzymes.
Description
Racemase and epimerase activity, acting on carbohydrates and derivatives (GO:0016857) is a molecular function that catalyzes the inversion of stereochemistry at one or more chiral centers within carbohydrate molecules. This activity is fundamental to the interconversion of sugar nucleotides, modification of cell surface glycans, and degradation of complex polysaccharides. Researchers study these enzymes to understand bacterial cell wall assembly, host-microbe interactions, and metabolic pathways. The importance of GO:0016857 extends to biotechnology, where engineered epimerases are used to produce rare sugars and bioactive oligosaccharides. In this article, we provide a comprehensive overview of the definition, mechanisms, key genes, disease relevance, and research methods for this GO term.
racemase and epimerase activity, acting on carbohydrates and derivatives At A Glance
| GO ID | GO:0016857 |
|---|---|
| GO term | racemase and epimerase activity, acting on carbohydrates and derivatives |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Catalysis of stereochemical inversion at chiral centers in carbohydrates |
| Representative enzymes | UDP-N-acetylglucosamine 2-epimerase, UDP-galactose 4-epimerase, mannuronate C-5 epimerase |
| Cofactors | Some require NAD+ or NADP+; others are metal-dependent |
| Subcellular location | Cytoplasm, periplasm, or membrane-associated depending on organism |
What Is GO:0016857?
According to QuickGO, GO:0016857 encompasses catalytic activity that alters the configuration of one or more chiral centers in a carbohydrate molecule. This includes racemases, which invert stereochemistry at a single center to produce a racemic mixture, and epimerases, which invert stereochemistry at one specific chiral center in a molecule with multiple centers. These enzymes act on carbohydrates and their derivatives, such as sugar nucleotides, monosaccharides, and polysaccharides.
Why Is racemase and epimerase activity, acting on carbohydrates and derivatives Important in Cell Biology?
GO:0016857 is critical for diverse biological processes, including bacterial cell wall biosynthesis, host immune evasion, and carbohydrate metabolism. Inhibiting these enzymes can disrupt pathogen viability, making them attractive antibiotic targets. In humans, defects in epimerases cause metabolic disorders such as galactosemia. Moreover, these enzymes are used in industrial biocatalysis to synthesize rare sugars and glycoconjugates.
• Essential for bacterial cell wall integrity and virulence.
• Involved in human metabolic disorders like galactosemia.
• Target for antibiotic development due to unique bacterial pathways.
• Enables production of rare sugars and bioactive carbohydrates.
• Plays a role in gut microbial polysaccharide degradation.
• Regulates cell surface glycan diversity and immune recognition.
• Provides mechanistic insights into enzyme catalysis and protein evolution.
• Facilitates biotechnological applications in food and pharmaceutical industries.
What Happens During racemase and epimerase activity, acting on carbohydrates and derivatives?
Substrate Binding and Recognition
In simple terms: The enzyme grabs the sugar molecule in a specific way.
The enzyme binds its carbohydrate substrate through a combination of hydrogen bonds, hydrophobic interactions, and sometimes metal coordination. For example, UDP-N-acetylglucosamine 2-epimerase binds UDP-GlcNAc in a pocket that positions the C2 hydroxyl for inversion. Similarly, mannuronate C-5 epimerase recognizes alginate polymers and binds a single mannuronate residue for epimerization.
Chiral Center Inversion
In simple terms: The enzyme flips the shape of the sugar at one specific spot.
Catalysis involves breaking and reforming bonds to invert stereochemistry. In UDP-galactose 4-epimerase, a conserved tyrosine residue acts as a general acid/base, while NAD+ mediates a transient oxidation-reduction to invert the C4 configuration. In mannuronate C-5 epimerase, a conserved histidine and arginine pair facilitates proton abstraction and donation at C5.
Product Release and Conformational Changes
In simple terms: After the flip, the enzyme lets go of the changed sugar.
Domain movements are often required for product release. In Staphylococcus aureus UDP-N-acetylglucosamine 2-epimerase, the energy landscape of domain movement reveals that a large conformational change opens the active site for product exit. This step can be rate-limiting and is regulated by substrate availability.
Cofactor Regeneration and Cofactor-Independent Mechanisms
In simple terms: Some enzymes need a helper molecule, others do not.
Some epimerases, like UDP-galactose 4-epimerase, use NAD+ as a cofactor that is regenerated after each catalytic cycle. In contrast, mannuronate C-5 epimerase and xylose isomerase operate without a cofactor, relying on acid-base chemistry and metal ions for catalysis.
Key Genes Involved in GO:0016857 racemase and epimerase activity, acting on carbohydrates and derivatives
The following genes encode enzymes with racemase or epimerase activity acting on carbohydrates and derivatives, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GALE | UDP-galactose 4-epimerase; interconverts UDP-galactose and UDP-glucose | Mutations cause galactosemia; target for inhibitor design |
| GNE | UDP-N-acetylglucosamine 2-epimerase; regulates sialic acid biosynthesis | Involved in sialuria and hereditary inclusion body myopathy |
| AlgE1 | Mannuronate C-5 epimerase; modifies alginate in Pseudomonas aeruginosa | Target for anti-biofilm agents |
| XylA | Xylose isomerase; converts xylose to xylulose | Used in high-fructose corn syrup production |
| RpiB | Ribose-5-phosphate isomerase; interconverts ribose-5-phosphate and ribulose-5-phosphate | Potential drug target in bacteria |
| UDP-glucose dehydrogenase | Oxidizes UDP-glucose to UDP-glucuronic acid | Involved in glycosaminoglycan biosynthesis |
| Cellobiose 2-epimerase | Epimerizes cellobiose to epilactose | Biotechnological production of prebiotics |
| β-1,4-mannooligosaccharide phosphorylase | Phosphorolyzes mannooligosaccharides | Gut microbial mannan degradation |
| UDP-N-acetylglucosamine 2-epimerase | Catalyzes interconversion of UDP-GlcNAc and UDP-ManNAc | Bacterial cell wall biosynthesis |
| dTDP-4-dehydrorhamnose 3,5-epimerase | Epimerizes dTDP-4-keto-6-deoxyglucose | Streptococcal virulence |
| GDP-mannose 4,6-dehydratase | Dehydrates GDP-mannose to GDP-4-keto-6-deoxymannose | Precursor for fucose synthesis |
| UDP-glucuronate 4-epimerase | Interconverts UDP-glucuronate and UDP-galacturonate | Plant cell wall biosynthesis |
| Mannose-6-phosphate isomerase | Interconverts mannose-6-phosphate and fructose-6-phosphate | Metabolic disorders |
| L-fucose isomerase | Converts L-fucose to L-fuculose | Bacterial fucose metabolism |
| D-arabinose isomerase | Converts D-arabinose to D-ribulose | Rare sugar production |
| L-ribose isomerase | Converts L-ribose to L-ribulose | Pharmaceutical intermediate synthesis |
| UDP-galactopyranose mutase | Interconverts UDP-galactopyranose and UDP-galactofuranose | Mycobacterial cell wall |
| dTDP-glucose 4,6-dehydratase | Dehydrates dTDP-glucose to dTDP-4-keto-6-deoxyglucose | Antibiotic target |
How Is racemase and epimerase activity, acting on carbohydrates and derivatives Regulated?
The activity of racemases and epimerases is regulated at multiple levels. In bacteria, expression of genes like gne and galE is controlled by transcriptional regulators responsive to nutrient availability and stress. Allosteric regulation by nucleotide sugars modulates enzyme activity; for example, UDP-GlcNAc 2-epimerase is feedback-inhibited by its product UDP-ManNAc. Post-translational modifications, such as phosphorylation, can also affect catalytic efficiency. In eukaryotic cells, these enzymes are regulated by metabolic flux and compartmentalization.
racemase and epimerase activity, acting on carbohydrates and derivatives and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GALE | Type III galactosemia | Patient-derived fibroblasts; GALE knockout mice |
| GNE | Sialuria; hereditary inclusion body myopathy | GNE knock-in mice; iPSC-derived muscle cells |
| AlgE1 | Pseudomonas aeruginosa biofilm infections | AlgE1 knockout P. aeruginosa; lung infection models |
| XylA | Rare sugar metabolism | XylA overexpression in E. coli; enzyme kinetics |
| Cellobiose 2-epimerase | Prebiotic production | Recombinant enzyme in food-grade bacteria |
Galactosemia
Mutations in GALE, encoding UDP-galactose 4-epimerase, cause type III galactosemia, a metabolic disorder characterized by accumulation of galactose metabolites and severe clinical symptoms. The enzyme's catalytic mechanism involving NAD+ and a conserved tyrosine is disrupted by these mutations.
Bacterial Infections
UDP-N-acetylglucosamine 2-epimerase is essential for the synthesis of N-acetylmannosamine, a precursor of sialic acid and cell wall components in pathogenic bacteria such as Staphylococcus aureus. Inhibitors targeting this enzyme are being explored as antibiotics.
Cystic Fibrosis and Biofilm Formation
AlgE1, a mannuronate C-5 epimerase, modifies alginate in Pseudomonas aeruginosa, contributing to biofilm formation and chronic lung infections in cystic fibrosis patients. Understanding its mechanism aids in developing anti-biofilm therapies.
Metabolic Disorders and Rare Sugars
Enzymes like xylose isomerase and cellobiose 2-epimerase are used to produce rare sugars with health benefits, such as allulose and epilactose. Their dysregulation can affect gut microbial metabolism and host health.
From racemase and epimerase activity, acting on carbohydrates and derivatives-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GALE knockout affect galactose metabolism? | GALE knockout HEK293 cells; galactose tolerance assay |
| How does GNE point mutation affect sialic acid synthesis? | GNE knock-in HeLa cells; sialic acid quantification |
| Can AlgE1 inhibition prevent biofilm formation? | AlgE1 knockout Pseudomonas aeruginosa; biofilm assay |
| What is the role of xylose isomerase in rare sugar production? | XylA overexpression in E. coli; HPLC analysis |
| Does cellobiose 2-epimerase improve prebiotic properties? | Knock-in of cellobiose 2-epimerase in Bifidobacterium; growth assays |
| How does UDP-glucose dehydrogenase regulate glycosaminoglycan synthesis? | CRISPR knockout in CHO cells; glycan profiling |
How to Study the racemase and epimerase activity, acting on carbohydrates and derivatives Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme kinetics | Catalytic efficiency, inhibition | Characterizing wild-type and mutant enzymes |
| X-ray crystallography | 3D structure, active-site geometry | Mechanistic studies |
| Molecular dynamics | Conformational changes, energy barriers | Domain movement analysis |
| CRISPR knockout | Gene function, metabolic consequences | Galactosemia modeling |
| Metabolomics | Sugar nucleotide levels | Pathway flux analysis |
| Glycomics | Cell surface glycan composition | Host-microbe interaction studies |
| Site-directed mutagenesis | Residue-specific roles | Catalytic mechanism dissection |
| High-throughput screening | Inhibitor discovery | Antibiotic development |
Enzyme Kinetics and Spectrophotometric Assays
Enzyme activity is measured by monitoring NADH/NADPH absorbance changes or using coupled assays. For UDP-galactose 4-epimerase, a coupled reaction with UDP-glucose dehydrogenase allows continuous monitoring at 340 nm. These methods determine kinetic parameters and inhibitor efficacy.
Structural Biology and Molecular Dynamics
X-ray crystallography and cryo-EM reveal active-site architecture and conformational changes. Molecular dynamics simulations, as applied to Staphylococcus aureus UDP-N-acetylglucosamine 2-epimerase, map the energy landscape of domain movements. Site-directed mutagenesis validates key residues.
CRISPR-Cas9 Genome Editing
Knockout, point mutation, and knock-in models are generated to study gene function in cells and organisms. For example, GALE knockout cells accumulate galactose-1-phosphate, mimicking galactosemia. CRISPR screens can identify synthetic lethal interactions.
Metabolomics and Glycomics
Mass spectrometry-based metabolomics quantifies sugar nucleotides and intermediates. Glycomics analyzes cell surface glycans to assess epimerase impact. These methods are crucial for linking enzyme activity to cellular phenotypes.
How CRISPR Can Be Used to Study GO:0016857 racemase and epimerase activity, acting on carbohydrates and derivatives
Knockout
CRISPR-Cas9 knockout of GALE or GNE eliminates enzyme activity, causing accumulation of upstream metabolites. These models are used to study metabolic disorders and validate drug targets.
Point Mutation
Introducing disease-associated point mutations (e.g., GALE p.V94M) via CRISPR base editing recapitulates partial enzyme deficiency. These models help dissect catalytic residues and genotype-phenotype relationships.
Knock-in
Knock-in of tagged or fluorescent versions of epimerases enables live-cell imaging and proteomic analysis. For example, GFP-tagged AlgE1 allows tracking of alginate modification in Pseudomonas aeruginosa.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression boosts enzyme levels to study gain-of-function effects, such as increased sialic acid production in GNE-overexpressing cells.
How EDITGENE Supports racemase and epimerase activity, acting on carbohydrates and derivatives Research
Researchers studying racemase and epimerase activity, acting on carbohydrates and derivatives-related genes often need to determine whether a candidate gene is causally involved in a specific pathway or disease. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for racemase and epimerase activity, acting on carbohydrates and derivatives research.
Frequently Asked Questions About racemase and epimerase activity, acting on carbohydrates and derivatives
What is GO:0016857?
GO:0016857 is a Gene Ontology molecular function term for racemase and epimerase activity that alters the configuration of chiral centers in carbohydrates and derivatives.
What genes are involved in racemase and epimerase activity?
Key genes include GALE, GNE, AlgE1, XylA, and cellobiose 2-epimerase, among others.
What diseases are linked to epimerase deficiencies?
GALE mutations cause type III galactosemia; GNE mutations are linked to sialuria and hereditary inclusion body myopathy.
How can I study racemase and epimerase activity in the lab?
Common methods include enzyme kinetics, CRISPR knockout, metabolomics, and structural biology.
What is the difference between a racemase and an epimerase?
Racemases invert stereochemistry at a single chiral center to produce a racemic mixture, while epimerases invert one specific center in a molecule with multiple centers.
Are there CRISPR models for GALE?
Yes, GALE knockout and point mutation models are available to study galactosemia.
What cofactors do carbohydrate epimerases use?
Some use NAD+ (e.g., UDP-galactose 4-epimerase), while others are metal-dependent or cofactor-independent.
How does AlgE1 contribute to biofilm formation?
AlgE1 modifies alginate by epimerizing mannuronate residues, which is essential for biofilm structure in Pseudomonas aeruginosa.
Can epimerases be targeted for antibiotics?
Yes, enzymes like UDP-N-acetylglucosamine 2-epimerase are essential for bacterial cell wall synthesis and are promising antibiotic targets.
What bioinformatics tools analyze CRISPR screens for epimerases?
EDITGENE provides custom bioinformatics pipelines for hit identification and pathway analysis.
Conclusion
GO:0016857 represents a fundamental enzymatic activity with broad biological and biomedical significance. From bacterial pathogenesis to human metabolic disorders, racemases and epimerases are critical players. Advances in CRISPR genome editing and structural biology continue to unravel their mechanisms, offering new therapeutic and biotechnological opportunities. EDITGENE stands ready to support your research with tailored CRISPR models and bioinformatics solutions.
References
- 1. Petersen AB et al.. 2025. Mode of Action of AlgE1: A Modular Mannuronate C-5 Epimerase.. Biochemistry 64(14):3030-3044 PMID: 40549830
- 2. de Azevedo EC et al.. 2019. Energy landscape of the domain movement in Staphylococcus aureus UDP-N-acetylglucosamine 2-epimerase.. J Struct Biol 207(2):158-168 PMID: 31088716
- 3. Campbell RE et al.. 1997. Properties and kinetic analysis of UDP-glucose dehydrogenase from group A streptococci. Irreversible inhibition by UDP-chloroacetol.. J Biol Chem 272(6):3416-22 PMID: 9013585
- 4. Kawahara R et al.. 2012. Metabolic mechanism of mannan in a ruminal bacterium, Ruminococcus albus, involving two mannoside phosphorylases and cellobiose 2-epimerase: discovery of a new carbohydrate phosphorylase, β-1,4-mannooligosaccharide phosphorylase.. J Biol Chem 287(50):42389-99 PMID: 23093406
- 6. Lambeir AM et al.. 1992. Protein engineering of xylose (glucose) isomerase from Actinoplanes missouriensis. 2. Site-directed mutagenesis of the xylose binding site.. Biochemistry 31(24):5459-66 PMID: 1610792
- 7. Wong YH et al.. 1979. p-(Bromoacetamido)phenyl uridyl pyrophosphate: an active-site-directed irreversible inhibitor for uridine diphosphate galactose 4-epimerase.. Biochemistry 18(24):5332-6 PMID: 391265
